My watch list  

PerkinElmer appoints President & Chief Operating Officer


PerkinElmer announced that its board of directors has named Prahlad Singh president and chief operating officer, effective January 1, 2019. In his expanded position, Dr. Singh will have responsibility for both the Discovery and Analytical Solutions (DAS) and Diagnostics operating divisions of the Company. This change is being made to better facilitate synergies across the businesses to identify incremental growth opportunities, create operating efficiencies, and most importantly, accelerate the pace of innovation across the Company. Dr. Singh, along with the leaders of the Company’s corporate functions, will continue to report to Robert F. Friel, PerkinElmer’s chairman and chief executive officer.

“It is clear that technologies, applications, and customer needs are converging across DAS and Diagnostics as our customers’ businesses evolve and the lines between therapeutics, diagnostics, food, and digital health are intersecting,” said Friel. “The opportunities for DAS to become an enabler of the sciences of Diagnostics, and vice-versa, continue to grow. Prahlad’s track record of consistently driving strong results operationally, commercially and strategically makes him well qualified to take on this important role. I look forward to working with him as he helps both the Diagnostics and DAS businesses better innovate breakthrough solutions and exceptionally serve our customers, ultimately driving greater value across our markets.”

Dr. Singh joined PerkinElmer in 2014 as president of the Diagnostics business. He was elected an officer of PerkinElmer in 2016 and executive vice president in March 2018. Dr. Singh served as general manager of GE Healthcare’s Women’s Health Business, responsible for the mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and M&A at both GE and Philips Healthcare. From 1995 to 2007, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol Myers Squibb Medical Imaging which included managing the Asia Pacific and Middle East regions.

Facts, background information, dossiers
  • personnel changes
More about PerkinElmer
  • News

    PerkinElmer appoints Chief Financial Officer

    PerkinElmer, Inc. announced the appointment of James M. Mock to senior vice president and chief financial officer (CFO), effective May 1, 2018. Andy Wilson, PerkinElmer’s current senior vice president and CFO, who previously announced his retirement from PerkinElmer, will remain with the Co ... more

    PerkinElmer Completes Acquisition of EUROIMMUN

    PerkinElmer, Inc. announced that the Company has completed its previously announced acquisition of EUROIMMUN Medical Laboratory Diagnostics AG . PerkinElmer originally announced its intent to acquire EUROIMMUN on June 19, 2017. more

    PerkinElmer to acquire EUROIMMUN for approximately $1.3 Billion

    PerkinElmer, Inc. announced that it has entered into a definitive agreement to acquireEUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN. The total purchase price of the transaction based on all outstanding share ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE